JP2020529193A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529193A5
JP2020529193A5 JP2019571019A JP2019571019A JP2020529193A5 JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5 JP 2019571019 A JP2019571019 A JP 2019571019A JP 2019571019 A JP2019571019 A JP 2019571019A JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5
Authority
JP
Japan
Prior art keywords
dna
amount
subject
threshold
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019571019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038604 external-priority patent/WO2018237078A1/en
Publication of JP2020529193A publication Critical patent/JP2020529193A/ja
Publication of JP2020529193A5 publication Critical patent/JP2020529193A5/ja
Pending legal-status Critical Current

Links

JP2019571019A 2017-06-20 2018-06-20 ドナー特異的セルフリーdnaを用いる移植対象における状態の評価 Pending JP2020529193A (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201762522560P 2017-06-20 2017-06-20
US201762522556P 2017-06-20 2017-06-20
US201762522547P 2017-06-20 2017-06-20
US62/522,560 2017-06-20
US62/522,556 2017-06-20
US62/522,547 2017-06-20
US201762542787P 2017-08-08 2017-08-08
US201762542790P 2017-08-08 2017-08-08
US62/542,790 2017-08-08
US62/542,787 2017-08-08
US201762546798P 2017-08-17 2017-08-17
US201762546872P 2017-08-17 2017-08-17
US201762546848P 2017-08-17 2017-08-17
US62/546,798 2017-08-17
US62/546,872 2017-08-17
US62/546,848 2017-08-17
US201762571709P 2017-10-12 2017-10-12
US201762571715P 2017-10-12 2017-10-12
US62/571,709 2017-10-12
US62/571,715 2017-10-12
US201762576641P 2017-10-24 2017-10-24
US62/576,641 2017-10-24
US201862632960P 2018-02-20 2018-02-20
US62/632,960 2018-02-20
US201862653261P 2018-04-05 2018-04-05
US62/653,261 2018-04-05
PCT/US2018/038604 WO2018237078A1 (en) 2017-06-20 2018-06-20 Assessing conditions in transplant subjects using donor-specific cell-free dna

Publications (2)

Publication Number Publication Date
JP2020529193A JP2020529193A (ja) 2020-10-08
JP2020529193A5 true JP2020529193A5 (https=) 2021-07-29

Family

ID=63047415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571019A Pending JP2020529193A (ja) 2017-06-20 2018-06-20 ドナー特異的セルフリーdnaを用いる移植対象における状態の評価

Country Status (8)

Country Link
US (1) US20210139988A1 (https=)
EP (1) EP3642367A1 (https=)
JP (1) JP2020529193A (https=)
CN (1) CN111094593A (https=)
AU (1) AU2018288835A1 (https=)
CA (1) CA3067634A1 (https=)
IL (1) IL271458A (https=)
WO (1) WO2018237078A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020206292A2 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509883A (ja) * 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
EP3741871A3 (en) 2012-04-19 2021-02-17 The Medical College of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
CA2922746A1 (en) * 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015058194A1 (en) * 2013-10-18 2015-04-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Allele specific pcr assay for detection of nucleotide variants
WO2015069933A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Similar Documents

Publication Publication Date Title
JP2020529193A5 (https=)
JP2020524519A5 (https=)
JP2020529194A5 (https=)
Azakie et al. Improving outcomes of the Fontan operation in children with atrial isomerism and heterotaxy syndromes
JP2020529193A (ja) ドナー特異的セルフリーdnaを用いる移植対象における状態の評価
Theuerle et al. Utility of the ACC/AHA lesion classification as a predictor of procedural, 30‐day and 12‐month outcomes in the contemporary percutaneous coronary intervention era
KR102347561B1 (ko) 우울증과 연관된 급성관상동맥증후군 장기예후 검사방법 및 진단키트
Daud et al. Microvascular loss and diastolic dysfunction in severe symptomatic cardiac allograft vasculopathy
Azzawi et al. Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients
Beller et al. Does preoperative troponin level impact outcomes after coronary artery bypass grafting?
Clausen et al. Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects
Chopra et al. Emerging role of cell-free DNA in kidney transplantation
Kanamori et al. Noninvasive graft monitoring using donor‐derived cell‐free DNA in Japanese liver transplantation
Richmond et al. Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults
Harskamp et al. Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery
Lietz et al. Current understanding and management of allograft vasculopathy
Deshpande et al. Evaluating threshold for donor fraction cell‐free DNA using clinically available assay for rejection in pediatric and adult heart transplantation
Bonnet et al. Sudden cardiac death after heart transplantation: a population-based study
Böhmer et al. Absolute quantification of donor-derived cell-free DNA following pediatric and adult heart transplantation
Cho et al. Quilty lesions in the endomyocardial biopsies after heart transplantation
Doucet et al. Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: analysis from the EXCEL trial
Pradhan et al. Telomere length is associated with adverse atrial remodeling in patients with atrial fibrillation
Floré et al. Intravascular ultrasound of the proximal left anterior descending artery is sufficient to detect early cardiac allograft vasculopathy
Angelini et al. Discordance between pre and post cardiac transplant diagnosis: implications for pre-and postoperative decision making
Bahniwal et al. Diagnostic approach to elevated dd-cfDNA with reassuring EMB in heart transplantation